The Impact of Enteral Versus Oral Protein Feeding on Muscle Protein Synthesis in Healthy Young Males and Females

University of Exeter30 enrolled

Overview

The present study will seek to quantify the muscle protein synthetic response to a protein beverage consumed orally or through a nasogastric tube in healthy, young individuals.

Thirty healthy, young volunteers will receive a stable isotope tracer infusion (8.5h) combined with repeated blood and muscle sampling, in order to measure muscle protein synthesis rate in the postabsorptive state, and following oral placebo ingestion (n=10), oral protein ingestion (n=10), or enteral protein administration (n=10).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Oral PlaceboOTHER

A placebo beverage will be consumed orally

Oral ProteinOTHER

A protein beverage will be consumed orally

Enteral ProteinOTHER

A protein beverage will be consumed via a naso-gastric feeding tube

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18-40 years of age * Body mass index between 18.5 and 30 Exclusion Criteria: * Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes) * Any diagnosed cardiovascular disease * Elevated blood pressure at the time of screening. (An average systolic blood pressure reading of ≥140 mmHg over two or more measurements and an average diastolic blood pressure of ≥90 mmHg over two or more measurements) * Chronic use of any prescribed or over the counter pharmaceuticals (that may modulate muscle protein metabolism). This excludes oral contraceptives and contraceptive devices. * A personal or family history of epilepsy, seizures or schizophrenia. * Presence of an ulcer in the stomach or gut and/or strong history of indigestion * Known pre-existing liver disease/condition * Any known disorders in muscle metabolism * Regular use of nutritional supplements * Allergy to lidocaine * Allergy to milk * Current paracetamol use (i.e. use of paracetamol more than once a week) * Pregnancy

Locations (1)

University of Exeter

Exeter, Devon, United Kingdom

Outcomes

Primary Outcomes

Postprandial muscle protein synthesis

Muscle protein synthesis rate (FSR) following ingestion of a placebo or protein supplement

Time frame: 5 hours

Secondary Outcomes

Postabsorptive muscle protein synthesis

Muscle protein synthesis rate (FSR, in %/h) during a 2 hour fasting period

Time frame: 2 hours

Whole-body protein synthesis

Whole-body protein synthesis, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)

Time frame: 7 hours

Whole-body protein breakdown

Whole-body protein breakdown, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)

Time frame: 7 hours

Whole-body protein oxidation

Whole-body protein oxidation, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)

Time frame: 7 hours

Whole-body protein net balance

Whole-body protein net balance, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)

Time frame: 7 hours

Gastric emptying rate

Gastric emptying rate following ingestion of a placebo or protein drink

Time frame: 5 hours

Blood glucose concentration

Blood glucose concentration in the postabsorptive and postprandial phase following placebo/protein ingestion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.